Understanding the listing of Lih-Bun Pharmaceutical (09637) on the Hong Kong Stock Exchange with just one picture.

According to the Wise Financial APP, the Hong Kong stock "first stock of innovative medicine for kidney disease" Liban Pharmaceuticals (09637) will be listed from June 18th to June 24th, 2026, and is expected to officially begin trading on the Hong Kong Stock Exchange at 9:00 am on June 29th. This innovative pharmaceutical company specializing in kidney disease not only has a complete pipeline matrix of "1 commercial product + 7 clinical stage candidate drugs", but also has gathered 11 cornerstone investors spanning global sovereign funds, century-old asset management, professional life sciences funds, and industrial capital, setting a new ceiling in the Hong Kong biopharmaceutical sector, which has been struggling recently.